OTHER PUBLICATIONS & ABSTRACTS
Other Data
Evidence / Other
Association Between Genomic Recurrence Risk and Well-Being Among Breast Cancer Patients
PUBLICATION: BMC Cancer. 2013 Jun 18;13:295. doi: 10.1186/1471-2407-13-295. AUTHORS: Retรจl V.P., Groothuis-Oudshoorn C.G., Aaronson N.K., Brewer N.T., Rutgers E.J., van Harten W.H. SUMMARY: Based on MINDACT: Women (n = 347, response rate 62%) reported high satisfaction with and a good understanding of the GEP information they received. Read more: Retรจl Read More
Multigene Assays and Molecular Markers in Breast Cancer: Systematic Review of Health Economic Analyses
PUBLICATION: Breast Cancer Res Treat. 2013 Jun;139(3):621-37. doi: 10.1007/s10549-013-2559-1. Epub 2013 May 31. AUTHORS: Rouzier R., Pronzato P., Chรฉreau E., Carlson J., Hunt B., Valentine W.J. SUMMARY: Systematic Review: The review identified 29 publications that reported evaluations of two assays: Oncotype DX(ยฎ) and MammaPrint. Studies of both tests provided evidence Read More
MammaPrint Feasibility in a Large Tertiary Urban Medical Center: An Initial Experience
PUBLICATION: Scientifica (Cairo). 2012; 2012: 942507. Published online 2012 Dec 31. doi: 10.6064/2012/942507. AUTHORS: C. Francisco Espinel, Shaughn Keating, Hanina Hibshoosh, Bret Taback, Kathie-Ann Joseph, Mahmoud El-Tamer, and Sheldon Feldman SUMMARY: This study indicates that using MP/TP assay is feasible in a tertiary care center but there may be utility Read More
Lobular Histology and Response to Neoadjuvant Chemotherapy in Invasive Breast Cancer
PUBLICATION: Breast Cancer Res Treat. 2012 Nov;136(1):35-43. doi: 10.1007/s10549-012-2233-z. Epub 2012 Sep 8. AUTHORS: Lips E.H., Mukhtar R.A., Yau C., de Ronde J.J., Livasy C., Carey L.A., Loo C.E., Vrancken-Peeters M.J., Sonke G.S., Berry D.A., Van't Veer L.J., Esserman L.J., Wesseling J., Rodenhuis S., Shelley Hwang E.; I-SPY TRIAL Investigators. Read More
Comparison of Molecular Subtyping with BluePrint, MammaPrint, and TargetPrint to Local Clinical Subtyping in Breast Cancer Patients
PUBLICATION: Ann Surg Oncol. 2012 Oct;19(10):3257-63. doi: 10.1245/s10434-012-2561-6. Epub 2012 Aug 15. AUTHORS: Nguyen B., Cusumano P.G., Deck K., Kerlin D., Garcia A.A., Barone J..L, Rivera E., Yao K., de Snoo F.A., van den Akker J., Stork-Sloots L., Generali D. SUMMARY: The concordance between BluePrint and IHC/FISH subtyping was 94% Read More
Economic Evaluation of the 70-gene Prognosis-Signature (MammaPrintยฎ) in Hormone Receptor-Positive, Lymph Node-Negative, Human Epidermal Growth Factor Receptor Type 2-Negative Early Stage Breast Cancer in Japan
PUBLICATION: Breast Cancer Res Treat. 2012 Jun;133(2):759-68. doi: 10.1007/s10549-012-1979-7. AUTHORS: Kondo M., Hoshi S.L., Ishiguro H., Toi M. SUMMARY: The introduction of the assay into Japanese practice of ER+, LNโ, HER2โ ESBC treatment by including it to Japanโs social health insurance benefit package has a reasonable chance to be judged Read More
Cost Effectiveness of Gene Expression Profiling for Early Stage Breast Cancer: a Decision-Analytic Mode
PUBLICATION: Cancer. 2012 Oct 15;118(20):5163-70. doi: 10.1002/cncr.27443. Epub 2012 Feb 22. AUTHORS: Yang M., Rajan S., Issa A.M. SUMMARY: The model suggested that MammaPrint is a more costโeffective GEP test compared with Oncotype DX at a threshold willingnessโtoโpay of $50,000 per QALY. Read more: Yang et al_2012_Cancer_Cost Effectiveness of Gene Read More